
Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
15/5/2025
0:00
4:14
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
Altri episodi di "Neurology Today in 5"
Non perdere nemmeno un episodio di “Neurology Today in 5”. Iscriviti all'app gratuita GetPodcast.